跳至主要内容
临床试验/NCT02708004
NCT02708004已完成1 期

A Single-center, Double-blind, Randomized, Placebo-controlled, Two-way Crossover Study to Assess Body Fluid Homeostasis After Administration of ACT-132577 in Healthy Subjects

Idorsia Pharmaceuticals Ltd.1 个研究点 分布在 1 个国家目标入组 24 人开始时间: 2016年6月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
入组人数
24
试验地点
1
主要终点
Body weight

研究概览

简要总结

This clinical study will be conducted to evaluate the effect of ACT-132577 on fluid homeostasis in healthy subjects.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Other
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 45 Years(Adult)
性别
Male
接受健康志愿者

入选标准

  • Signed informed consent
  • Healthy on the basis of medical history, physical examination, cardiovascular assessments and hematology, clinical chemistry, and urinalysis tests
  • Body mass index between 20.0 and 25.0 kg/m2 (inclusive) at screening

排除标准

  • Any circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol

研究组 & 干预措施

ACT-132577

Experimental

3 different dose levels

干预措施: Aprocitentan (Drug)

Placebo

Placebo Comparator

Matching active drug

干预措施: Placebo (Other)

结局指标

主要结局

Body weight

时间窗: from Day 1 to Day 9

Change from baseline

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验